Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 269

Sort by

Sort Order Select

Journal Articles

Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia

Grigorios Tsaknakis, Anna Gallì, Stavros Papadakis, Peggy Kanellou, Chiara Elena, Gabriele Todisco, Elisa Bono, Ettore Rizzo, Elisabetta Molteni, Irene Fragiadaki, Irene Mavroudi, Charalampos Pontikoglou, Anastasios Batas, Stella Maxouri, Emmanouela Linardaki, Nektarios Tavernarakis, Luca Malcovati, Helen A. Papadaki

Blood (2021) 138 (14): 1249–1257.

https://doi.org/10.1182/blood.2021010815

Published: 2021

Includes: Supplemental data

Journal Articles

What can Heraclitus tell us about AML?

Arnold Ganser

Blood (2021) 137 (20): 2719–2720.

https://doi.org/10.1182/blood.2021011264

Published: 2021

Journal Articles

Prognosis of comutations in IDH1/2 -mutated AML

Blood (2021) 137 (20): 2856.

https://doi.org/10.1182/blood.2021012066

Published: 2021

Journal Articles

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Blood (2021) 137 (20): 2827–2837.

https://doi.org/10.1182/blood.2020010165

Published: 2021

Includes: Supplemental data

Journal Articles

Taking aim at IDH in fitter patients with AML

Andrew H. Wei, Naval Daver

Blood (2021) 137 (13): 1706–1707.

https://doi.org/10.1182/blood.2020009361

Published: 2021

Journal Articles

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Blood (2021) 137 (13): 1792–1803.

https://doi.org/10.1182/blood.2020007233

Published: 2021

Includes: Supplemental data

Journal Articles

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1 -mutant acute myeloid leukemia

Blood (2020) 135 (7): 463–471.

https://doi.org/10.1182/blood.2019002140

Published: 2020

Includes: Supplemental data

Journal Articles

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Namrata S Chandhok, MD, Wei Wei, MD, Stephanie Halene, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 1374.

https://doi.org/10.1182/blood-2019-130033

Published: 2019

Journal Articles

Idh2R140Q Cooperates with NHD13 to Induce Immature T Cell Leukemia By Targeting Early T Cell Progenitors or DN2 Thymocytes

Vijay Negi, PhD, Liat Goldberg, PhD, Yang Jo Chung, PhD, Masahiro Onozawa, MD, Peter D. Aplan, MD

Blood (2019) 134 (Supplement_1): 1346.

https://doi.org/10.1182/blood-2019-128675

Published: 2019

Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 674.

https://doi.org/10.1182/blood-2019-124360

Published: 2019

Journal Articles

Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses

Hongfang Wang, PhD, Sung Choe, PhD, Courtney D. DiNardo, MD MSc, Eytan M. Stein, MD, Stéphane de Botton, MD PhD, Amir T. Fathi, MD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Lynn Quek, MD PhD, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 541.

https://doi.org/10.1182/blood-2019-122703

Published: 2019

Journal Articles

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia

Sung Choe, PhD, Hongfang Wang, PhD, Courtney D. DiNardo, MD MSc, Eytan M. Stein, MD, Stephane De Botton, Amir T. Fathi, MD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Lynn Quek, MD PhD, Zenon Konteatis, PhD, Lenny Dang, PhD, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 545.

https://doi.org/10.1182/blood-2019-122671

Published: 2019

Journal Articles

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Megha Ramappan, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 2670.

https://doi.org/10.1182/blood-2019-131949

Published: 2019

Journal Articles

Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia

Maher Albitar, MD, Marina Y Konopleva, MD PhD, Ivan De Dios, BS, Jeffrey Justin Estella, BS, MS, Spiraggelos Antzoulatos, Steven M. Kornblau, MD, Antonio Cavazos, Sanam Loghavi, MD, Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MDMSc

Blood (2019) 134 (Supplement_1): 2730.

https://doi.org/10.1182/blood-2019-127383

Published: 2019

Journal Articles

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Scott R. Daigle, MS, Sung Choe, PhD, Lynn Quek, MD PhD, Courtney D. DiNardo, MDMSc, Anthony Stein, MD, Eytan M. Stein, MD, Amir T. Fathi, MD, Olga Frankfurt, MD, Andre C. Schuh, MD, Hagop M. Kantarjian, MD, Vickie Zhang, PhD, Thomas Winkler, MD, Paresh Vyas, MD PhD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 2706.

https://doi.org/10.1182/blood-2019-122590

Published: 2019

Journal Articles

DNA Methylation Profiling of AML Reveals Epigenetic Subgroups with Distinct Clinical Outcome

Sebastian Vosberg, Paul Kerbs, MSc, Vindi Jurinovic, MSc, Klaus H. Metzeler, MD, Susanne Amler, PhD, Cristina Sauerland, Dennis Görlich, PhD, Wolfgang E. Berdel, MD, Jan Braess, MD, Wolfgang Hiddemann, MD PhD, Karsten Spiekermann, MD, Tobias Herold, MD, Philipp A. Greif, MD PD

Blood (2019) 134 (Supplement_1): 2715.

https://doi.org/10.1182/blood-2019-130047

Published: 2019

Journal Articles

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Pau Montesinos Fernandez, MD PhD, Christian Recher, MD PhD, Vadim Doronin, MD, Rodrigo T. Calado, MD PhD, Jun Ho Jang, MD PhD, Yasushi Miyazaki, MD PhD, Jianxiang Wang, MD, Diego A Gianolio, PhD, Scott R. Daigle, MS, Thomas Winkler, MD, Vickie Zhang, PhD, Peter Paschka, MD

Blood (2019) 134 (Supplement_1): 2593.

https://doi.org/10.1182/blood-2019-123045

Published: 2019

Journal Articles

Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets

Cassandra M Kerr, MS, Vera Adema, PhD, Wencke Walter, PhD, Stephan Hutter, PhD, Christina A. Snider, BA, Yasunobu Nagata, MD PhD, Manja Meggendorfer, PhD, Claudia Haferlach, MD, Valeria Visconte, PhD, Mikkael A. Sekeres, MD MS, Thomas Laframboise, PhD, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1703.

https://doi.org/10.1182/blood-2019-126866

Published: 2019

Journal Articles

Comparison of Three Assays for Identification of IDH Mutations in AML

Sara Ribeiro, BSc, Dorte Wren, PhDFRCPath, Lisa Thompson, PhD MSc, FIBMS, Michael Hubank, PhD, David Taussig, PhD MRCP, FRCPath

Blood (2019) 134 (Supplement_1): 5195.

https://doi.org/10.1182/blood-2019-126494

Published: 2019

Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 4254.

https://doi.org/10.1182/blood-2019-123946

Published: 2019

NARROW

Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia

What can Heraclitus tell us about AML?

Prognosis of comutations in IDH1/2 -mutated AML

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Taking aim at IDH in fitter patients with AML

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1 -mutant acute myeloid leukemia

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Idh2R140Q Cooperates with NHD13 to Induce Immature T Cell Leukemia By Targeting Early T Cell Progenitors or DN2 Thymocytes

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

DNA Methylation Profiling of AML Reveals Epigenetic Subgroups with Distinct Clinical Outcome

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets

Comparison of Three Assays for Identification of IDH Mutations in AML

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only